- Home
- STTK vs CADL Comparison
STTK vs CADL Comparison
Compare STTK & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STTK | CADL |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.9M | 280.3M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | STTK | CADL |
|---|---|---|
| Price | $4.03 | $5.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $6.20 | ★ $19.43 |
| AVG Volume (30 Days) | 375.1K | ★ 900.1K |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.32 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,721,000.00 | $125,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 245.26 | N/A |
| 52 Week Low | $0.69 | $4.25 |
| 52 Week High | $4.89 | $9.13 |
Technical Indicators
Market Signals| Indicator | STTK | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 51.33 | 42.03 |
| Support Level | $3.52 | $4.44 |
| Resistance Level | $4.23 | $5.34 |
| Average True Range (ATR) | 0.28 | 0.31 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 58.62 | 35.08 |
Price Performance
Historical ComparisonAbout STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.